Select Language
MERTK
MERTK Overview
| English Name | Tyrosine-protein kinase Mer | Approved Drugs | 1 |
| Drugs in Clinical Trials | 8 | Target Synonym | EC 2.7.10，MER，MERTK，C-Mer Proto-Oncogene Tyrosine Kinase，Receptor Tyrosine Kinase MerTK，Tyrosine-Protein Kinase Mer，EC 2.7.10.1，STK Kinase，EC:2.7.10.1，Proto-oncogene c-Mer，MER Proto-Oncogene， Tyrosine Kinase，MER Receptor Tyrosine Kinase，Tyro12，C-Eyk，C-Mer，RP38，c-Mer Tyrosine Kinase |
| Highest Development Stage | Approved | ||
| English Name | Tyrosine-protein kinase Mer |
| Target Synonym | EC 2.7.10，MER，MERTK，C-Mer Proto-Oncogene Tyrosine Kinase，Receptor Tyrosine Kinase MerTK，Tyrosine-Protein Kinase Mer，EC 2.7.10.1，STK Kinase，EC:2.7.10.1，Proto-oncogene c-Mer，MER Proto-Oncogene， Tyrosine Kinase，MER Receptor Tyrosine Kinase，Tyro12，C-Eyk，C-Mer，RP38，c-Mer Tyrosine Kinase |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 8 |
| Highest Development Stage | Approved |
MERTK Product List
- Product Category
Protein (5)
- Product Status
Launched (5)
- Species
Human (2)Mouse (2)Cynomolgus (1)
- Tag
His Tag (2)Fc Tag (3)
- Conjugate
Unconjugated (5)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT MEK-H5253 |  Human | HEK293 | Human MERTK / Mer Protein, Fc Tag |  |  |  |
HOT MEK-H52H6 | Human | HEK293 | Human MERTK / Mer Protein, His Tag |  | |  |
HOT MEK-M52H9 |  Mouse | HEK293 | Mouse MERTK / Mer Protein, His Tag (MALS verified) |  | | |
MEK-M5253 | Mouse | HEK293 | Mouse MERTK / Mer Protein, Fc Tag (MALS verified) |  | | |
MEK-C5253 |  Cynomolgus | HEK293 | Cynomolgus MERTK / Mer Protein, Fc Tag (MALS verified) |  | |
Total: 5
- 1
MERTK Background
Tyrosine-protein kinase Mer(MERTK) is a member of the TYRO3/AXL/MER (TAM) receptor kinase family and encodes a transmembrane protein with two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains, and one tyrosine kinase domain. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.
MERTK Synonyms
MERTK,Mer
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516 | Phase 3 Clinical | Mirati Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | Details |
| MRX-2843 | UNC-2371; UNC-2025; MRX-2843 | Phase 2 Clinical | University Of North Carolina At Chapel Hill | Carcinoma, Non-Small-Cell Lung; Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplastic Processes; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Tamnorzatinib | ONO-7475 | Phase 2 Clinical | Ono Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancreatic Neoplasms; Solid tumours | Details |
| Adrixetinib | Q-702 | Phase 2 Clinical | Lead Discovery Center GmbH, Max Planck Institute of Biochemistry, Vichem Chemie | Blastic Plasmacytoid Dendritic Cell Neoplasm; Carcinoma, Hepatocellular; Central Nervous System Lymphoma; Erdheim-Chester Disease; Esophageal Neoplasms; Graft vs Host Disease; Hematologic Neoplasms; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Histiocytosis, Sinus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Lymphoma, Follicular; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Neoplasms, Plasma Cell; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia | Details |
| INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Nifitinib Tosilate | Phase 1 Clinical | Sichuan University, Yangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland